Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

11 evidence topics · 9 sources

Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin

“The phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 28-day study evaluated lanifibranor in participants with T2DM who were on metformin monotherapy (Figure 1)” (opens the source at this quote in a new tab)

“Lanifibranor (400, 800, and 1400 mg) consistently induced dose- and time-related increases in total and HMW adiponectin (Figure 4), which is indicative of PPARγ engagement” (opens the source at this quote in a new tab)

“Exposures of about 50 µg·h/mL for area under the curve from time zero to the last measurable concentration (AUC0-τ) and about 7 µg/mL for the maximal concentration (Cmax) resulted in more than 200% increase for the percent change from baseline total adiponectin” (opens the source at this quote in a new tab)

“Dose-related improvements in insulin, pro-insulin, and insulin resistance were observed with lanifibranor, with a significant reduction in pro-insulin with 1400 mg versus placebo.” (opens the source at this quote in a new tab)

“Reductions in average and postprandial blood glucose were observed at 1400 mg (Table 2), which were consistent with the PPARγ insulin-sensitizing mechanism” (opens the source at this quote in a new tab)

“Lanifibranor 800 and 1400 mg showed significant (P<0.05) change from baseline in high-density lipoprotein (HDL) cholesterol and triglycerides compared with placebo (Figure 5 and Table 2)” (opens the source at this quote in a new tab)

“At Day 28, lanifibranor showed no fluid-retention signals (pedal edema, ankle foot volume, ankle circumference, or body-weight increase) versus placebo, with no changes in hematology, albumin, or brain natriuretic peptide (BNP; Table 3)” (opens the source at this quote in a new tab)

Mean (SD) percent change from baseline at day 28Lanifibranor 400 mg (n=17)Lanifibranor 800 mg (n=15)Lanifibranor 1400 mg (n=15)Placebo (n=14)
Triglycerides“–19.7 (33.9)”“–20.8 (23.5)”“–31.7 (31.2)”“–5.81 (27.6)”
HDL-C“13.4 (15.3)”“16.7 (17.2)”“27.7 (25.9)”“2.52 (12.2)”
Pro-insulin“–26.7 (35.6)”“–21.1 (45.0)”“–37.4 (26.3)”“–3.28 (49.9)”
Mean (SD) value reported for change from baseline at day 28Lanifibranor 400 mg (n=17)Lanifibranor 800 mg (n=15)Lanifibranor 1400 mg (n=15)Placebo (n=14)
Ankle foot volume, cm3“3.75 (14.51)”“–5.31 (15.51)”“3.91 (11.14)”“–5.42 (11.07)”
Body weight change at Day 28, kg“0.55 (1.97)”“0.11 (1.72)”“0.94 (2.05)”“–0.36 (2.68)”
Hemoglobin, g/L“–5.63 (4.81)”“–5.04 (6.75)”“–5.96 (5.55)”“–3.70 (5.29)”
Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE

“This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With placebo only 10% had moderate, and none high increase (Supplementary Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Adiponectin is a pleiotropic adipokine and PPARγ downstream mediator, while PPARα activity may affect adiponectin signaling through receptor upregulation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fasting high density lipoprotein cholesterol (HDL-C) increased significantly at treatment week 4 (TW4), maintained until EOT: patients receiving lanifibranor 1200 mg and 800 mg had an AMD at EOT of 0.10 mmol/L (95%CI: 0.03 to 0.16, p = 0.003, equivalent to 3.9 mg/dL) and 0.16 mmol/L (95%CI: 0.09 to 0.22, p < 0.001, equivalent to 6.2 mg/dL), respectively (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Systolic BP did not change significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote